Primecap Management’s 10x Genomics TXG Stock Holding History

Primecap Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30,000	Closed	-$262K	–	346
2025 Q1	$262K	Sell	30,000 -97,600	-76%	-$1.23M	﹤0.01%	332
2024 Q4	$1.83M	Sell	127,600 -167,800	-57%	-$2.65M	﹤0.01%	307
2024 Q3	$6.67M	Buy	295,400 +108,600	+58%	+$2.25M	﹤0.01%	276
2024 Q2	$3.63M	Buy	186,800 +107,400	+135%	+$2.81M	﹤0.01%	292
2024 Q1	$2.98M	Buy	79,400 +48,000	+153%	+$2.11M	﹤0.01%	301
2023 Q4	$1.76M	Buy	31,400 +1,300	+4%	+$56.6K	﹤0.01%	313
2023 Q3	$1.24M	Buy	+30,100	New	+$1.57M	﹤0.01%	314
2022 Q2	–	Sell	-3,300	Closed	-$251K	–	343
2022 Q1	$251K	Hold	3,300	–	–	﹤0.01%	337
2021 Q4	$492K	Sell	3,300 -4,350	-57%	-$666K	﹤0.01%	338
2021 Q3	$1.11M	Hold	7,650	–	–	﹤0.01%	328
2021 Q2	$1.5M	Hold	7,650	–	–	﹤0.01%	321
2021 Q1	$1.39M	Hold	7,650	–	–	﹤0.01%	318
2020 Q4	$1.08M	Hold	7,650	–	–	﹤0.01%	312
2020 Q3	$954K	Hold	7,650	–	–	﹤0.01%	303
2020 Q2	$683K	Hold	7,650	–	–	﹤0.01%	298
2020 Q1	$477K	Buy	+7,650	New	+$597K	﹤0.01%	285

Other funds holding TXG

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Primecap Management's TXG Position: Q2 2025 in Review

Primecap Management sold out of 10x Genomics (TXG) in Q2 2025, closing a stake of 30,000 shares — an estimated $262K sold.

Primecap Management first reported a position in TXG in Q1 2020 and held it in 16 quarters. The position peaked at $6.67M in Q3 2024. 297 funds tracked by Wall St. Rank hold TXG as of Q2 2025.

Primecap Management reported no remaining 10x Genomics position as of Q2 2025 after selling out during the quarter.
Primecap Management sold 30,000 10x Genomics shares in Q2 2025, an estimated $262K.
Primecap Management first reported a position in 10x Genomics in Q1 2020 and held it in 16 quarters.
Primecap Management's 10x Genomics position peaked at $6.67M in Q3 2024.
297 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2025.

Based on Primecap Management's 13F filing for Q2 2025, filed 11 Aug 2025.